Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisFish oil supplements for rheumatoid arthritisMethotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysisBiologicals in rheumatoid arthritis: current and futureEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateUtilizing regulatory T cells against rheumatoid arthritisEffect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trialsBiologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study.2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Early start and stop of biologics: has the time come?Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.APLAR rheumatoid arthritis treatment recommendations.Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.Cost per responder of TNF-α therapies in Germany.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).Making smart investment decisions in clinical researchTwo-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trialHigh remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trialNot better but quite good: effects on work loss of combination treatment for rheumatoid arthritis with and without biological agents.Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis.Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy.Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritisCurrent immunotherapy in rheumatoid arthritis.Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.Is non-biological treatment of rheumatoid arthritis as good as biologics?Iguratimod for the treatment of rheumatoid arthritis in Japan.Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.
P2860
Q24185797-7395AB03-79B8-4763-AB1F-B0FEEC1D04EBQ24197686-96DD9300-B0CD-4C51-AB26-179909F17410Q26751187-18E57C2A-C19A-480E-B44E-8B4A86D068BAQ26780316-1035D919-A3D2-4E9B-B585-032AB1ECCDFEQ26859134-7AD08878-F79B-401C-8C79-AF6A0B3A7FB0Q27009990-8131D805-C70E-4EAF-A75B-DC8841A104D6Q28543128-7671C6DF-C1B5-4143-B4AE-6A46BF2E2155Q30234528-94B1C4C8-BF5E-4D09-92CA-B8EA055C8638Q30235341-952766B7-AD3F-4DF2-865C-B40C1A0CE689Q30812918-99AE8244-2F8B-4252-B199-A5AFBEE239AEQ30882161-8280F9AE-5B65-4829-A3BE-A5453A5EEE70Q31122982-C2D1106F-B6DF-4332-A41B-CF2FE3A18653Q34354935-42D18306-355C-4DC2-A5E2-C9DF34747710Q34500921-12219DF8-826A-4386-B694-1130E41107A3Q35087279-DB21EF70-860A-44A3-B04D-B9136943C650Q35174817-45794B75-8B58-41F6-AF53-0DF7542DDD27Q35605415-2EC5CDFB-22C1-4D53-AB07-B77E37A9CD3EQ35605424-C4190C56-E191-4293-9C07-2D2F033C6AE8Q35762912-5C62F3A7-4459-46F2-BA6A-9EAA2D402A18Q35792901-F1D4E557-27FA-4E0E-B454-5343C01718C0Q35891851-EAD8E935-6B93-4F00-8D12-86F3AE8BE81EQ35981155-2B637E63-9C08-4779-8CD6-68C902043414Q36195284-11244A18-7833-4632-B51C-9A78FBE46F88Q36409914-88B3470F-CD03-413B-8A11-C30980D80E47Q36485495-7397D56E-406D-4213-A4EC-A042FD111BDBQ36577396-41D4A440-B8D6-474B-B496-F74CD8B36420Q36657901-6BDF7C98-1B77-406D-8DFC-880A92A2C98EQ37116737-FC0D5A50-95C2-412A-92E4-1A332156F1D1Q37579322-F4C223C6-9768-4ED5-81E7-577A025B8F28Q37587412-0D782AC9-F20A-40E2-AF6D-D23001DD494BQ37745676-909F37C5-C243-4E23-A178-7E47D262249BQ38072312-31456092-3242-4AC0-9698-2878F97BB36AQ38091288-9A30F975-D40C-4430-A48A-AD42E128CB38Q38133655-6E9D7035-F504-45CE-BF61-0004BD416F7FQ38176549-1AB79474-E0E8-4BE0-BA4B-3B128D60AEEAQ38320157-F60AB418-0E20-41AA-A7DA-F31ADF8ABFCEQ38385089-2948A0AD-F65C-4E2A-BDD1-83862C123370Q38386610-B474D749-0BAB-4C46-9D14-93333EF158B9Q38533964-789D6C78-1BDF-46F6-AC5D-15000D4B70FBQ38645738-E4995E9B-B5D0-4C4F-B21C-C3BDA0C8003C
P2860
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Conventional combination treat ...... , parallel-group Swefot trial.
@en
type
label
Conventional combination treat ...... , parallel-group Swefot trial.
@en
prefLabel
Conventional combination treat ...... , parallel-group Swefot trial.
@en
P2093
P1433
P1476
Conventional combination treat ...... , parallel-group Swefot trial.
@en
P2093
Ingemar F Petersson
Johan Bratt
Kristina Albertsson
Kristina Forslind
Pierre Geborek
Sofia Ernestam
Swefot study group
P304
P356
10.1016/S0140-6736(12)60027-0
P407
P577
2012-03-29T00:00:00Z